What is NUWIQ®️ for Hemophilia A Treatment? | Official Patient Website

A Recombinant Factor VIII Produced in a Human Cell Line

NUWIQ is a recombinant antihemophilic factor [blood coagulation factor VIII (Factor VIII)] used to treat Hemophilia A in adults and children. NUWIQ is FDA-approved for

on-demand treatment and control of bleeding episodes
perioperative management of bleeding
routine prophylaxis to reduce the frequency of bleeding episodes.

NUWIQ is not indicated for the treatment of von Willebrand Disease.

NUWIQ—A Natural Choice for Your Hemophilia A Treatment

Proven effective in controlling bleeding¹
Zero antibodies, also known as inhibitors, developed in studies with Previously Treated Patients (PTPs) who switched to NUWIQ¹
Shown to be safe in Previously Untreated Patients (PUPs)
Potential to extend your dosing intervals with Personalized Prophylaxis with NUWIQ
NUWIQ has convenient and flexible dosing
Ease of administration

References

NUWIQ Full Prescribing Information. Paramus, NJ: Octapharma; rev 2021.

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Use

NUWIQ^® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ^® is not indicated for the treatment of von Willebrand Disease.

Contraindications

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions

The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.

Please See NUWIQ full Prescribing Information. Instructions For Use